An algorithm recommendation for the pharmacological management of allergic rhinitis in the UK: a consensus statement from an expert panel

Brian Lipworth (Lead / Corresponding author), Jon Newton, Bhasker Ram, Iain Small, Jürgen Schwarze

Research output: Contribution to journalArticle

4 Citations (Scopus)
106 Downloads (Pure)

Abstract

Allergic rhinitis (AR) is a frequent presenting problem in primary care in the UK, and has increased in prevalence over the last 30 years. When symptomatic, patients report significant reduction in their quality of life and impairment in school and work performance. Achieving adequate symptom control is pivotal to successful AR management, and relies mostly on pharmacotherapy. While it is recognised that most mild-moderate AR symptoms can be managed successfully in primary care, important gaps in GP training in relation to AR have been identified. With the availability of new effective combination therapies, such as the novel intranasal formulation of azelastine hydrochloride and fluticasone propionate in a single device (Dymista® 30 ; Meda), the majority of AR symptoms can be treated in the primary care setting. The primary objective of this consensus statement is to improve diagnosis and treatment of AR in primary care, and offer guidance on appropriate referral of difficult-to-treat patients into secondary care. The guidance provided herein outlines a sequential treatment pathway for AR in primary care that incorporates a considered approach to improve the management of AR symptoms and improve compliance and patient satisfaction with therapy. Adherence with this care pathway has the potential to limit the cost of providing effective AR management in the UK by avoiding unnecessary treatments and investigations, and avoiding the need for costly referrals to secondary care in the majority of AR cases. The fundamentals presented in this consensus article should apply in most healthcare settings.
Original languageEnglish
Article number3
Pages (from-to)1-8
Number of pages8
JournalNPJ Primary Care Respiratory Medicine
Volume27
DOIs
Publication statusPublished - 23 Jan 2017

Fingerprint

Pharmacology
Primary Health Care
Secondary Care
azelastine
Referral and Consultation
Allergic Rhinitis
Therapeutics
Patient Satisfaction
Compliance
Quality of Life
Delivery of Health Care
Costs and Cost Analysis
Drug Therapy
Equipment and Supplies

Keywords

  • Respiratory tract diseases
  • Therapeutics

Cite this

@article{ca85d6f7fd414059a9695c25d0087823,
title = "An algorithm recommendation for the pharmacological management of allergic rhinitis in the UK: a consensus statement from an expert panel",
abstract = "Allergic rhinitis (AR) is a frequent presenting problem in primary care in the UK, and has increased in prevalence over the last 30 years. When symptomatic, patients report significant reduction in their quality of life and impairment in school and work performance. Achieving adequate symptom control is pivotal to successful AR management, and relies mostly on pharmacotherapy. While it is recognised that most mild-moderate AR symptoms can be managed successfully in primary care, important gaps in GP training in relation to AR have been identified. With the availability of new effective combination therapies, such as the novel intranasal formulation of azelastine hydrochloride and fluticasone propionate in a single device (Dymista{\circledR} 30 ; Meda), the majority of AR symptoms can be treated in the primary care setting. The primary objective of this consensus statement is to improve diagnosis and treatment of AR in primary care, and offer guidance on appropriate referral of difficult-to-treat patients into secondary care. The guidance provided herein outlines a sequential treatment pathway for AR in primary care that incorporates a considered approach to improve the management of AR symptoms and improve compliance and patient satisfaction with therapy. Adherence with this care pathway has the potential to limit the cost of providing effective AR management in the UK by avoiding unnecessary treatments and investigations, and avoiding the need for costly referrals to secondary care in the majority of AR cases. The fundamentals presented in this consensus article should apply in most healthcare settings.",
keywords = "Respiratory tract diseases, Therapeutics",
author = "Brian Lipworth and Jon Newton and Bhasker Ram and Iain Small and J{\"u}rgen Schwarze",
year = "2017",
month = "1",
day = "23",
doi = "10.1038/s41533-016-0001-y",
language = "English",
volume = "27",
pages = "1--8",
journal = "NPJ Primary Care Respiratory Medicine",
issn = "2055-1010",
publisher = "Nature Publishing Group",

}

An algorithm recommendation for the pharmacological management of allergic rhinitis in the UK : a consensus statement from an expert panel . / Lipworth, Brian (Lead / Corresponding author); Newton, Jon; Ram, Bhasker; Small, Iain; Schwarze, Jürgen.

In: NPJ Primary Care Respiratory Medicine, Vol. 27, 3, 23.01.2017, p. 1-8.

Research output: Contribution to journalArticle

TY - JOUR

T1 - An algorithm recommendation for the pharmacological management of allergic rhinitis in the UK

T2 - a consensus statement from an expert panel

AU - Lipworth, Brian

AU - Newton, Jon

AU - Ram, Bhasker

AU - Small, Iain

AU - Schwarze, Jürgen

PY - 2017/1/23

Y1 - 2017/1/23

N2 - Allergic rhinitis (AR) is a frequent presenting problem in primary care in the UK, and has increased in prevalence over the last 30 years. When symptomatic, patients report significant reduction in their quality of life and impairment in school and work performance. Achieving adequate symptom control is pivotal to successful AR management, and relies mostly on pharmacotherapy. While it is recognised that most mild-moderate AR symptoms can be managed successfully in primary care, important gaps in GP training in relation to AR have been identified. With the availability of new effective combination therapies, such as the novel intranasal formulation of azelastine hydrochloride and fluticasone propionate in a single device (Dymista® 30 ; Meda), the majority of AR symptoms can be treated in the primary care setting. The primary objective of this consensus statement is to improve diagnosis and treatment of AR in primary care, and offer guidance on appropriate referral of difficult-to-treat patients into secondary care. The guidance provided herein outlines a sequential treatment pathway for AR in primary care that incorporates a considered approach to improve the management of AR symptoms and improve compliance and patient satisfaction with therapy. Adherence with this care pathway has the potential to limit the cost of providing effective AR management in the UK by avoiding unnecessary treatments and investigations, and avoiding the need for costly referrals to secondary care in the majority of AR cases. The fundamentals presented in this consensus article should apply in most healthcare settings.

AB - Allergic rhinitis (AR) is a frequent presenting problem in primary care in the UK, and has increased in prevalence over the last 30 years. When symptomatic, patients report significant reduction in their quality of life and impairment in school and work performance. Achieving adequate symptom control is pivotal to successful AR management, and relies mostly on pharmacotherapy. While it is recognised that most mild-moderate AR symptoms can be managed successfully in primary care, important gaps in GP training in relation to AR have been identified. With the availability of new effective combination therapies, such as the novel intranasal formulation of azelastine hydrochloride and fluticasone propionate in a single device (Dymista® 30 ; Meda), the majority of AR symptoms can be treated in the primary care setting. The primary objective of this consensus statement is to improve diagnosis and treatment of AR in primary care, and offer guidance on appropriate referral of difficult-to-treat patients into secondary care. The guidance provided herein outlines a sequential treatment pathway for AR in primary care that incorporates a considered approach to improve the management of AR symptoms and improve compliance and patient satisfaction with therapy. Adherence with this care pathway has the potential to limit the cost of providing effective AR management in the UK by avoiding unnecessary treatments and investigations, and avoiding the need for costly referrals to secondary care in the majority of AR cases. The fundamentals presented in this consensus article should apply in most healthcare settings.

KW - Respiratory tract diseases

KW - Therapeutics

U2 - 10.1038/s41533-016-0001-y

DO - 10.1038/s41533-016-0001-y

M3 - Article

C2 - 28115736

VL - 27

SP - 1

EP - 8

JO - NPJ Primary Care Respiratory Medicine

JF - NPJ Primary Care Respiratory Medicine

SN - 2055-1010

M1 - 3

ER -